{"entity":{"id":"nct07388524","kind":"trial","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","aka":[],"tldr":"A phase 3 trial of atezolizumab in lung cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial is a phase 3, randomised interventional study registered as NCT07388524 by National Cancer Institute (NCI), with a registry enrolment figure of 336 participants, started 2027-03-02 and due to reach its primary completion in 2032-09-30. Interventions recorded: Atezolizumab; Atezolizumab and Recombinant Human Hyaluronidase; Biospecimen Collection; Computed Tomography; Patient Observation. Conditions listed: Lung Non-Small Cell Carcinoma. Primary outcome: Disease-free survival. Lung eligibility wording from the registry: \"* Pathologically stage IA3 or IB NSCLC per American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 9th edition\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07388524","url":"https://clinicaltrials.gov/study/NCT07388524"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07388524","phase":"3","setting":"Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)","sponsor":"National Cancer Institute (NCI)","enrolled":336,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07388524/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}